Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets
about
Emerging critical role of molecular testing in diagnostic genitourinary pathologyConcurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionOverexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.Temporal changes in the pathologic assessment of prostate cancer.Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men.MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cellsPTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.The cost implications of prostate cancer screening in the Medicare population.Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches.MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.Disruption of prostate epithelial differentiation pathways and prostate cancer development.Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.The prostate cancer-up-regulated Myc-associated zinc-finger protein (MAZ) modulates proliferation and metastasis through reciprocal regulation of androgen receptor.Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression.4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer.MYC and Prostate CancerMucinous and secondary tumors of the prostate.Cost implications of PSA screening differ by age.PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications
P2860
Q27021371-EEFD170C-04F8-4E2F-8A53-2C6E30F19050Q28743074-184ECB57-E6EE-4A29-9249-A26704B3AC7CQ33685303-19B72700-8180-4BC5-A07F-2289B5A99C60Q34454426-0783644D-66F3-42DC-A148-C4C0B4A72D52Q36520474-546287FC-8748-481D-A0FE-67115C0F4D13Q36551167-591762B8-DDC2-4827-B425-A4F13B65F6EFQ36959452-FECA6C03-E265-47C2-9565-7D85009CFEFFQ37367858-5ECBA321-C440-4DE0-9135-14F2294C9F42Q37402386-DAB3F0E8-2F75-4D60-A96B-2124A451F9B3Q37910715-80FCD0ED-C6A6-4F7B-8427-9DC72CAF4792Q37972706-86D7A8E8-6232-446F-82DA-930C763BB4F6Q38047420-7D5CC93B-4E97-4217-957A-1963B9CB2AC0Q38147318-6CAEAFD1-02C9-4556-9EA5-19AAC3526F0AQ38160495-EE0F20A3-8D4E-41D3-98E6-933757040740Q38721818-5AF29214-FEB0-478E-81BA-48FC408B4CFBQ39162205-56AD0E0C-4032-4E2D-BD6B-E6384DD9F723Q39254195-3E6A8880-07A1-4081-9009-B51E4879FA70Q40920100-5A767BF3-C49E-4A3E-9CBC-2ABC731DA4A7Q41815304-995659EA-0D36-4765-9597-1E043289174DQ41860747-3FE77E6F-2D3F-4680-B4BF-EA2B1F3321F9Q42731671-BB1C2CEB-81F7-4F18-BEBB-719D2D9FF9C5Q47664729-E601A507-0797-47C0-AF33-292679FDB87AQ55032029-CFEB64B7-FD35-4368-A52D-9D09B612435FQ57790325-D59B0965-7EF5-4CDF-8EAA-15E7DC3C0C27
P2860
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Molecular alterations in prost ...... ostic, and therapeutic targets
@ast
Molecular alterations in prost ...... ostic, and therapeutic targets
@en
Molecular alterations in prost ...... ostic, and therapeutic targets
@nl
type
label
Molecular alterations in prost ...... ostic, and therapeutic targets
@ast
Molecular alterations in prost ...... ostic, and therapeutic targets
@en
Molecular alterations in prost ...... ostic, and therapeutic targets
@nl
prefLabel
Molecular alterations in prost ...... ostic, and therapeutic targets
@ast
Molecular alterations in prost ...... ostic, and therapeutic targets
@en
Molecular alterations in prost ...... ostic, and therapeutic targets
@nl
P2093
P2860
P3181
P1476
Molecular alterations in prost ...... ostic, and therapeutic targets
@en
P2093
Angelo M De Marzo
Cheryl M Koh
Srinivasan Yegnasubramanian
Tsuyoshi Iwata
William G Nelson
P2860
P304
P3181
P356
10.1097/PAP.0B013E31818A5C19
P407
P50
P577
2008-11-01T00:00:00Z